A continuing decline in sales of COVID-19 products clips revenue at Pfizer

Pfizer lost more than $2 billion in the third quarter as an expected COVID-19 product sales decline clipped revenue.

Sales of the drugmaker's COVID treatment Paxlovid and the vaccine Comirnaty slid 97% and 70%, respectively, as Pfizer, like its competitors, switched to selling on the commercial market instead of to governments.